Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Vivo Ventures Leads $30 Million Funding of Shanghai Jingfeng Pharma

publication date: Nov 5, 2012
Vivo Ventures, the California-China healthcare venture capital company, is the lead investor in a 190 million RMB ($30 million) funding round for Shanghai Jingfeng Pharmaceutical Co., according to Venture Wire. In January, Vivo closed Vivo Ventures VII, a $375 million fund. It pledged to allocate 45% of that to China life science companies. Founded in 2003, Shanghai Jingfeng Pharma is GMP-certified by the SFDA to make sodium hyaluronate API. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital